Logo image of GTHX

G1 THERAPEUTICS INC (GTHX) Stock Fundamental Analysis

NASDAQ:GTHX - Nasdaq - US3621LQ1099 - Common Stock - Currency: USD

7.15  0 (0%)

After market: 7.14 -0.01 (-0.14%)

Fundamental Rating

2

Taking everything into account, GTHX scores 2 out of 10 in our fundamental rating. GTHX was compared to 566 industry peers in the Biotechnology industry. GTHX may be in some trouble as it scores bad on both profitability and health. GTHX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GTHX has reported negative net income.
GTHX had a negative operating cash flow in the past year.
GTHX had negative earnings in each of the past 5 years.
GTHX had a negative operating cash flow in each of the past 5 years.
GTHX Yearly Net Income VS EBIT VS OCF VS FCFGTHX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M

1.2 Ratios

GTHX has a Return On Assets (-45.36%) which is comparable to the rest of the industry.
With a Return On Equity value of -182.03%, GTHX is not doing good in the industry: 67.14% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -45.36%
ROE -182.03%
ROIC N/A
ROA(3y)-58.78%
ROA(5y)-52.55%
ROE(3y)-151.24%
ROE(5y)-111.52%
ROIC(3y)N/A
ROIC(5y)N/A
GTHX Yearly ROA, ROE, ROICGTHX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

GTHX has a better Gross Margin (89.44%) than 92.44% of its industry peers.
GTHX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GTHX Yearly Profit, Operating, Gross MarginsGTHX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

2

2. Health

2.1 Basic Checks

GTHX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GTHX has been increased compared to 1 year ago.
The number of shares outstanding for GTHX has been increased compared to 5 years ago.
Compared to 1 year ago, GTHX has a worse debt to assets ratio.
GTHX Yearly Shares OutstandingGTHX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
GTHX Yearly Total Debt VS Total AssetsGTHX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

GTHX has an Altman-Z score of -8.24. This is a bad value and indicates that GTHX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.24, GTHX is doing worse than 72.76% of the companies in the same industry.
GTHX has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.
GTHX has a worse Debt to Equity ratio (1.34) than 80.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF N/A
Altman-Z -8.24
ROIC/WACCN/A
WACC11.45%
GTHX Yearly LT Debt VS Equity VS FCFGTHX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 2.48 indicates that GTHX has no problem at all paying its short term obligations.
GTHX has a worse Current ratio (2.48) than 71.53% of its industry peers.
A Quick Ratio of 2.12 indicates that GTHX has no problem at all paying its short term obligations.
GTHX has a worse Quick ratio (2.12) than 73.81% of its industry peers.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 2.12
GTHX Yearly Current Assets VS Current LiabilitesGTHX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

GTHX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.71%, which is quite impressive.
Looking at the last year, GTHX shows a very negative growth in Revenue. The Revenue has decreased by -34.74% in the last year.
The Revenue has been growing by 22.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)49.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-171.43%
Revenue 1Y (TTM)-34.74%
Revenue growth 3Y22.13%
Revenue growth 5YN/A
Sales Q2Q%-60.97%

3.2 Future

GTHX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.36% yearly.
Based on estimates for the next years, GTHX will show a quite strong growth in Revenue. The Revenue will grow by 15.53% on average per year.
EPS Next Y55.71%
EPS Next 2Y43.4%
EPS Next 3Y30.77%
EPS Next 5Y20.36%
Revenue Next Year-8.96%
Revenue Next 2Y8.16%
Revenue Next 3Y10.3%
Revenue Next 5Y15.53%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GTHX Yearly Revenue VS EstimatesGTHX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
GTHX Yearly EPS VS EstimatesGTHX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2 -3

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GTHX. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 133.52 indicates a quite expensive valuation of GTHX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of GTHX indicates a rather cheap valuation: GTHX is cheaper than 90.86% of the companies listed in the same industry.
GTHX is valuated expensively when we compare the Price/Forward Earnings ratio to 21.20, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 133.52
GTHX Price Earnings VS Forward Price EarningsGTHX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GTHX Per share dataGTHX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates GTHX does not grow enough to justify the current Price/Earnings ratio.
GTHX's earnings are expected to grow with 30.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.4%
EPS Next 3Y30.77%

More info and screens

0

5. Dividend

5.1 Amount

GTHX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

G1 THERAPEUTICS INC

NASDAQ:GTHX (9/17/2024, 8:10:49 PM)

After market: 7.14 -0.01 (-0.14%)

7.15

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2024-08-08/bmo
Earnings (Next)10-30 2024-10-30/amc
Inst Owners1.72%
Inst Owner Change-96.06%
Ins Owners13.3%
Ins Owner Change0%
Market Cap377.23M
Analysts74.55
Price Target7.29 (1.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.61%
Min EPS beat(2)4.63%
Max EPS beat(2)40.58%
EPS beat(4)3
Avg EPS beat(4)16.53%
Min EPS beat(4)-4.3%
Max EPS beat(4)40.58%
EPS beat(8)7
Avg EPS beat(8)33.92%
EPS beat(12)10
Avg EPS beat(12)23.38%
EPS beat(16)14
Avg EPS beat(16)22.11%
Revenue beat(2)0
Avg Revenue beat(2)-3.93%
Min Revenue beat(2)-6.99%
Max Revenue beat(2)-0.87%
Revenue beat(4)1
Avg Revenue beat(4)-2.9%
Min Revenue beat(4)-15.25%
Max Revenue beat(4)11.53%
Revenue beat(8)4
Avg Revenue beat(8)6.13%
Revenue beat(12)7
Avg Revenue beat(12)4.65%
Revenue beat(16)10
Avg Revenue beat(16)136.37%
PT rev (1m)58.89%
PT rev (3m)-15.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)24.07%
EPS NY rev (1m)-2.21%
EPS NY rev (3m)24.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.2%
Revenue NY rev (1m)2.96%
Revenue NY rev (3m)1.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 133.52
P/S 6.48
P/FCF N/A
P/OCF N/A
P/B 15.34
P/tB 15.34
EV/EBITDA N/A
EPS(TTM)-0.86
EYN/A
EPS(NY)0.05
Fwd EY0.75%
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS1.1
BVpS0.47
TBVpS0.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.36%
ROE -182.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.44%
FCFM N/A
ROA(3y)-58.78%
ROA(5y)-52.55%
ROE(3y)-151.24%
ROE(5y)-111.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.48
Quick Ratio 2.12
Altman-Z -8.24
F-Score3
WACC11.45%
ROIC/WACCN/A
Cap/Depr(3y)32.08%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.33%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-171.43%
EPS Next Y55.71%
EPS Next 2Y43.4%
EPS Next 3Y30.77%
EPS Next 5Y20.36%
Revenue 1Y (TTM)-34.74%
Revenue growth 3Y22.13%
Revenue growth 5YN/A
Sales Q2Q%-60.97%
Revenue Next Year-8.96%
Revenue Next 2Y8.16%
Revenue Next 3Y10.3%
Revenue Next 5Y15.53%
EBIT growth 1Y43.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.15%
EBIT Next 3Y133.69%
EBIT Next 5Y24.98%
FCF growth 1Y74.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.2%
OCF growth 3YN/A
OCF growth 5YN/A